Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.
In this study, researchers used immunophenotyping to explore the biomarkers associated with clinical characteristics in large vessel vasculitis.
Researchers suggest that temporal ultrasound may be an appealing choice for monitoring disease activity in patients with cranial giant cell arteritis treated with tocilizumab.
Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.
Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
Takayasu arteritis (TA) can manifest in childhood and the symptoms may be overlooked, leading to delay in diagnosis and poor outcomes. A study that included 40 children with TA provides insights on the diagnosis and treatment of this rare and potentially life-threatening condition.
